Instil Bio, Inc.

TIL

US45783C2008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
12.72 ^USD	+31.13%		+28.61%	+66.93%

Jul. 12	Instil Bio Shares Surge Following Rental Agreement with AstraZeneca	DJ
Jul. 12	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT

INSTIL BIO, INC. : Other Events (form 8-K)

March 10, 2023 at 03:48 pm EST

Item 8.01 Other Events.

Instil Bio, Inc. informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank.

--------------------------------------------------------------------------------

Latest news about Instil Bio, Inc.

Instil Bio Shares Surge Following Rental Agreement with AstraZeneca	Jul. 12	DJ
Sector Update: Health Care Stocks Rise in Afternoon Trading	Jul. 12	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	Jul. 12	MT
Traders Digest Big Bank Earnings, Stifling US Equity Futures Pre-Bell	Jul. 12	MT
Top Premarket Gainers	Jul. 12	MT
Instil Bio Signs Lease With AstraZeneca Pharmaceuticals at California Facility; Shares Rise After Hours	Jul. 11	MT
Instil Bio, Inc.(NasdaqCM:TIL) added to Russell 3000E Index	Jun. 30	CI
Instil Bio, Inc.(NasdaqCM:TIL) added to Russell Microcap Index	Jun. 30	CI
Instil Bio, Inc.(NasdaqCM:TIL) added to Russell Microcap Value Index	Jun. 30	CI
Instil Bio, Inc.(NasdaqCM:TIL) added to Russell 3000E Value Index	Jun. 30	CI
Baird Adjusts Price Target on Instil Bio to $32 From $54, Maintains Outperform Rating	May. 13	MT
Instil Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Instil Bio, Inc. Announces Board Changes	Apr. 26	CI
North American Morning Briefing : Stock Futures -2-	Apr. 15	DJ
Jefferies Downgrades Instil Bio to Hold From Buy	Apr. 12	MT
Instil Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Instil Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Instil Bio, Inc. Enters into Agreement with A Collaboration to Conduct Preclinical Manufacturing Feasibility Studies in the ITIL-306 Program	Jan. 16	CI
Instil Bio, Inc. Announces the Closure of Its UK Manufacturing and Clinical Operations	Jan. 16	CI
Instil Bio, Inc.(NasdaqCM:TIL) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Instil Bio Says 1-for-20 Reverse Stock Split to Take Effect on Dec. 7	Dec. 06	MT
Instil Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Instil Bio, Inc.(NasdaqCM:TIL) dropped from S&P Global BMI Index	23-09-18	CI
Instil Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
HC Wainwright Initiates Instil Bio With Buy Rating, $2 Price Target	23-06-29	MT

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.72 USD

Average target price

20.33 USD

Spread / Average Target

+59.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INSTIL BIO, INC.	+66.93%	82.73M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research

Instil Bio, Inc.

Equities

TIL

US45783C2008

Biotechnology & Medical Research

INSTIL BIO, INC. : Other Events (form 8-K)

Latest news about Instil Bio, Inc.

Chart Instil Bio, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research